KR100808433B1 - 항-염증 활성을 갖는 신규 이미다졸 - Google Patents

항-염증 활성을 갖는 신규 이미다졸 Download PDF

Info

Publication number
KR100808433B1
KR100808433B1 KR1020067024215A KR20067024215A KR100808433B1 KR 100808433 B1 KR100808433 B1 KR 100808433B1 KR 1020067024215 A KR1020067024215 A KR 1020067024215A KR 20067024215 A KR20067024215 A KR 20067024215A KR 100808433 B1 KR100808433 B1 KR 100808433B1
Authority
KR
South Korea
Prior art keywords
alkyl
formula
compound
haloalkyl
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067024215A
Other languages
English (en)
Korean (ko)
Other versions
KR20060129102A (ko
Inventor
까르멘 아르만사
꼰셉션 곤잘레즈
마 까르멘 또레스
Original Assignee
제이. 유라이어크 이 콤파니아 소시에떼아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이. 유라이어크 이 콤파니아 소시에떼아노님 filed Critical 제이. 유라이어크 이 콤파니아 소시에떼아노님
Publication of KR20060129102A publication Critical patent/KR20060129102A/ko
Application granted granted Critical
Publication of KR100808433B1 publication Critical patent/KR100808433B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020067024215A 1998-10-16 1999-10-15 항-염증 활성을 갖는 신규 이미다졸 Expired - Lifetime KR100808433B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP9802222 1998-10-16
ES9802222 1998-10-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020017004779A Division KR100715918B1 (ko) 1998-10-16 1999-10-15 항-염증 활성을 갖는 신규 이미다졸

Publications (2)

Publication Number Publication Date
KR20060129102A KR20060129102A (ko) 2006-12-14
KR100808433B1 true KR100808433B1 (ko) 2008-03-03

Family

ID=8305557

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020067024215A Expired - Lifetime KR100808433B1 (ko) 1998-10-16 1999-10-15 항-염증 활성을 갖는 신규 이미다졸
KR1020017004779A Expired - Lifetime KR100715918B1 (ko) 1998-10-16 1999-10-15 항-염증 활성을 갖는 신규 이미다졸

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020017004779A Expired - Lifetime KR100715918B1 (ko) 1998-10-16 1999-10-15 항-염증 활성을 갖는 신규 이미다졸

Country Status (20)

Country Link
US (1) US6838476B1 (enExample)
EP (1) EP1122243B1 (enExample)
JP (1) JP4480894B2 (enExample)
KR (2) KR100808433B1 (enExample)
AR (1) AR024222A1 (enExample)
AT (1) ATE275549T1 (enExample)
AU (1) AU6204899A (enExample)
BE (1) BE2011C024I2 (enExample)
BR (2) BRPI9914571B8 (enExample)
CA (1) CA2346847C (enExample)
CY (1) CY2011009I2 (enExample)
DE (2) DE69920028T2 (enExample)
DK (1) DK1122243T3 (enExample)
ES (1) ES2228109T3 (enExample)
FR (1) FR11C0028I2 (enExample)
HK (1) HK1039331B (enExample)
LU (1) LU91849I2 (enExample)
NO (2) NO319074B1 (enExample)
PT (1) PT1122243E (enExample)
WO (1) WO2000023426A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5261556A1 (es) 1999-12-08 2003-03-31 Pharmacia Corp Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
ES2159489B1 (es) 2000-03-23 2002-04-16 Uriach & Cia Sa J Nuevos derivados de imidazol con actividad antiinflamatoria.
ES2166710B1 (es) * 2000-04-25 2004-10-16 J. URIACH & CIA, S.A. Nuevos compuestos heterociclicos con actividad antiinflamatoria.
ES2184633B1 (es) * 2001-08-07 2004-08-01 J. URIACH & CIA, S.A. Procedimiento para la preparacion de derivados de 4-(imidazol-1-il) bencenosulfonamida.
MXPA04009961A (es) * 2002-04-12 2004-12-13 Pfizer Compuestos de imidazol como agentes anti-inflamatorios y analgesicos.
KR100804827B1 (ko) * 2002-05-17 2008-02-20 씨제이제일제당 (주) 티아졸리딘-4-온 유도체, 그 제조방법 및 약제학적 조성물
EP1542667B1 (en) * 2002-07-24 2012-03-07 PTC Therapeutics, Inc. Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
FR2881049B1 (fr) * 2005-01-24 2008-12-26 Vetoquinol Sa Sa Medicament destine a etre administre par voie orale comprenant un inhibiteur de la cyclo-oxygenase-2, et son procede de preparation
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
GB0806745D0 (en) * 2008-04-14 2008-05-14 Syngenta Participations Ag Novel imidazole derivatives
US8691866B2 (en) 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
US20110045101A1 (en) * 2009-05-06 2011-02-24 E.I. Du Pont De Nemours And Company Fungicidal substituted azoles
CN102464652B (zh) * 2010-11-02 2013-08-28 北京欧博方医药科技有限公司 咪唑衍生物、制备方法及用途
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar HYALURONIC ACID-CONJUGATED DIPALMITOYL PHOSPHATIDYL ETHANOLAMINE IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FOR TREATING OR ALLEVIATING INFLAMMATORY DISEASES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901908A (en) * 1970-12-28 1975-08-26 Ciba Geigy Corp 2-alkyl- and 2-cycloalkyl-4,5-bis-phenyl-imidazoles
IT1168008B (it) * 1981-07-31 1987-05-20 Zambon Spa Imidazol-eteri ed ester, procedimenti per prepararli e composizioni farmaceutiche che li contengono
US4576958A (en) * 1984-01-23 1986-03-18 E. I. Du Pont De Nemours And Company Antihypertensive 4,5-diaryl-1H-imidazole-2-methanol derivatives
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
GEP20032998B (en) * 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors

Also Published As

Publication number Publication date
JP4480894B2 (ja) 2010-06-16
BR9914571A (pt) 2001-11-06
DK1122243T3 (da) 2005-01-10
NO20011790L (no) 2001-06-14
FR11C0028I2 (fr) 2012-06-22
NO2011012I2 (no) 2013-05-06
EP1122243B1 (en) 2004-09-08
AU6204899A (en) 2000-05-08
KR20060129102A (ko) 2006-12-14
ATE275549T1 (de) 2004-09-15
US6838476B1 (en) 2005-01-04
EP1122243A1 (en) 2001-08-08
DE69920028D1 (de) 2004-10-14
KR100715918B1 (ko) 2007-05-08
JP2002527508A (ja) 2002-08-27
FR11C0028I1 (enExample) 2011-09-23
NO2011012I1 (no) 2011-08-08
AR024222A1 (es) 2002-09-25
PT1122243E (pt) 2004-12-31
HK1039331B (en) 2005-01-07
ES2228109T3 (es) 2005-04-01
BRPI9914571B1 (pt) 2011-10-18
DE69920028T2 (de) 2005-09-22
BRPI9914571A (pt) 2001-11-06
LU91849I2 (fr) 2011-09-27
NO20011790D0 (no) 2001-04-09
WO2000023426A1 (es) 2000-04-27
DE122011100028I1 (de) 2011-12-08
BRPI9914571B8 (pt) 2021-07-06
CA2346847A1 (en) 2000-04-27
CY2011009I1 (el) 2014-04-09
CY2011009I2 (el) 2014-04-09
HK1039331A1 (en) 2002-04-19
KR20010080186A (ko) 2001-08-22
NO319074B1 (no) 2005-06-13
BE2011C024I2 (enExample) 2019-03-05
CA2346847C (en) 2009-12-22

Similar Documents

Publication Publication Date Title
KR100715918B1 (ko) 항-염증 활성을 갖는 신규 이미다졸
JPH11302277A (ja) ピラゾール誘導体、その製法および医薬としてのその使用
TWI449696B (zh) 以５員雜環為主之ｐ３８激酶抑制劑
JPH09500137A (ja) 複数の治療特性を有するトリ置換イミダゾール
JP2003513961A (ja) シクロオキシゲナーゼ−２の阻害剤である５−アリール−１ｈ−１，２，４−トリアゾール化合物とそれを含む医薬品組成物
US5723485A (en) 1,2-Diarylindole derivatives, processes for their preparation and their uses in therapeutics
WO2008110891A2 (en) New heterocyclic compounds
US6670365B1 (en) Substituted imidazo 1,2a}azines as selective inhibitors of cox-2
CZ20011058A3 (cs) Deriváty 2-fenylpyran-4-onu
JP3142581B2 (ja) 新規ピロール誘導体
TW201028376A (en) 1-phenylpyrrole compounds
JP2013540780A (ja) イミダゾール誘導体並びにその製造法及び使用
US6743816B2 (en) Imidazole derivatives with anti-inflammatory activity
US7169929B2 (en) Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor
JP2002526494A (ja) 抗炎症剤及びサイトカイン分泌阻害剤として有用な２−アリールアルキルチオ−イミダゾール、２−アリールアルケニル−チオ−イミダゾール及び２−アリールアルキニル−チオ−イミダゾール
EP1281709B1 (en) Novel heterocyclic compounds with anti-inflammatory activity
WO2002092593A1 (fr) Derives de 4-(4-pyridazinyl)pyrazole
MXPA01003679A (en) Novel imidazoles with anti-inflammatory activity
KR100366169B1 (ko) 다중치료특성을갖는삼치환이미다졸

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20061117

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070109

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20071204

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20080222

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20080222

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20110119

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20120213

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20130201

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20130201

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20140203

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20140203

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20150223

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20150223

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20170217

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20170217

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20180213

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20180213

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20190214

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20190214

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20200415

Termination category: Expiration of duration